Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Go back to Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
(NASDAQ: XENE) Delayed: 35.64 -0.86 (2.36%)
Previous Close $36.50    52 Week High $9.75 
Open $36.62    52 Week Low $5.65 
Day High $36.62    P/E N/A 
Day Low $35.41    EPS $0.00 
Volume 155,478       

(NASDAQ: XENE) Delayed: 35.64 -0.86 (2.36%)
Previous Close $36.50    52 Week High $9.75 
Open $36.62    52 Week Low $5.65 
Day High $36.62    P/E N/A 
Day Low $35.41    EPS $0.00 
Volume 155,478